Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

IMPACT FACTOR 2017: 0.484
5-year IMPACT FACTOR: 0.484

CiteScore 2017: 0.53

SCImago Journal Rank (SJR) 2017: 0.154
Source Normalized Impact per Paper (SNIP) 2017: 0.264

ICV 2017: 152.94

Open Access
See all formats and pricing
More options …
Volume 9, Issue 5


Volume 10 (2015)

A case of myositis with immunological background associated with statin use

Dragana Protić
  • Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Snežana Baltić / Nada Stupar / Slavica Pavlov-Dolijanović / Snežana Mugoša / Zoran Todorović
  • Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-07-31 | DOI: https://doi.org/10.2478/s11536-013-0313-z


Statins might cause and/or aggravate the immune-mediated myositis in patients on long-term, stable treatment. We provide a case of polymyositis with an immunological background and gastrointestinal and urinary manifestations in patient on long-term, stable atorvastatin treatment for the past six years. The diagnose of polymyositis was established based on clinical symptoms and signs, electromyography and laboratory test results (elevated aspartate aminotransferase 279 U/L, reference range 0–40 U/L; alanine aminotransferase 198 U/L, 0–33 U/L; lactate dehydrogenase 2200 U/L, 103-227 U/L; creatine kinase 7820 U/L, 15–84 U/L; and positive antinuclear antibodies test, titer of 1:160, with suspect antisynthetase antibodies). Polymyositis was probably related to atorvastatin treatment (Naranjo score, 5). Other probable causes of the myositis were rejected. Coricosteroid therapy, methotrexate and supplementation with vitamin D did not improve the condition. The patient remained bedridden and died two months after the hospital discharge due to the acute myocardial infarction.

Keywords: Myositis; Atorvastatin; Vitamin D

  • [1] Hmelin A., Turgeon J., Hydrophilicity/Lipophlicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors, Trends. Pharmacol. Sci., 1998, 19, 26–37 http://dx.doi.org/10.1016/S0165-6147(97)01147-4CrossrefGoogle Scholar

  • [2] Todorovic Z., Nesic Z., Stojanović R., Basta-Jovanović G., Radojevic-Skodrić S., Velicković R., et al., Acute protective effects of simvastatin in the rat model of renal ischemia-reperfusion injury: it is never too late for the pretreatment, J. Pharmacol. Sci., 2008, 107, 465–470 http://dx.doi.org/10.1254/jphs.SC0070374CrossrefWeb of ScienceGoogle Scholar

  • [3] Hoffman K.B., Kraus C., Dimbil M., Beatrice A. Golomb B. A., A survey of the FDA’s AERS database regarding muscle and adverse events linked to the statin drug class. http://plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0042866. (accessed 2013 Jan 31) Web of ScienceGoogle Scholar

  • [4] Radcliffe K. A., Campbell W. W., Statin myopathy, Curr. Neurol. Neurosci. Rep., 2008, 8, 66–72 http://dx.doi.org/10.1007/s11910-008-0011-4Web of ScienceCrossrefGoogle Scholar

  • [5] Marcoff L., Thompson P., The Role of Coenzyme Q10 in Statin-Associated Myopathy, J. Am. Coll. Cardiol., 2007, 49, 2231–2237 http://dx.doi.org/10.1016/j.jacc.2007.02.049CrossrefGoogle Scholar

  • [6] Sathasivam S., Statin induced myotoxicity, Eur. J. Intern. Med., 2012, 23, 317–324 http://dx.doi.org/10.1016/j.ejim.2012.01.004CrossrefGoogle Scholar

  • [7] Padala S., Thompson P. D., Statins as a possible cause of inflammatory and necrotizing myopathies, Atherosclerosis., 2012, 222, 15–21 http://dx.doi.org/10.1016/j.atherosclerosis.2011.11.005Web of ScienceCrossrefGoogle Scholar

  • [8] Marshall J. B., Kretschmar J. M., Gerhardt D. C., Winship D. H., Winn D., Treadwell E.L., et al., Gastrointestinal manifestations of mixed connective tissue disease, Gastroenterology, 1990, 98, 1232–1238 PubMedGoogle Scholar

  • [9] Dalakas M. C., Hohlfeld R., Polymyositis and dermatomyositis, Lancet, 2003, 362, 971–982 http://dx.doi.org/10.1016/S0140-6736(03)14368-1CrossrefGoogle Scholar

  • [10] McKenney J. M., Dyslipidemias, atherosclerosis, and coronary heart disease, In: Koda-Kimble M. A (ed.), Applied therapeutics: the clinical use of drugs. 8th ed., Lippencott Williams & Wilkins, 2005 Google Scholar

  • [11] Hilton-Jones D., Myopathy associated with statin therapy, Neuromuscul. Disord., 2008, 18, 97–98 http://dx.doi.org/10.1016/j.nmd.2007.08.008CrossrefGoogle Scholar

  • [12] Naranjo C. A., Busto U., Sellers E. M., Sandor P., Ruiz I., Roberts E. A., et al., A method for estimating the probability of adverse drug reactions, Clin. Pharmacol. Ther., 1981, 30, 239–245 http://dx.doi.org/10.1038/clpt.1981.154CrossrefGoogle Scholar

  • [13] Anonymous. Real world drug outcomes, personalized. http://www.ehealthme.com/ds/Lipitor. (accessed 2013 Jan 15) Google Scholar

  • [14] Glueck C. J., Abuchaibe C., Wang P., Symptomatic myositis-myalgia in hypercholesterolemic statintreated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle, Med. Hypotheses, 2011, 77, 658–661 http://dx.doi.org/10.1016/j.mehy.2011.07.007Web of ScienceCrossrefGoogle Scholar

  • [15] Transfeldt E. E., Morley J.E., Segal F., Klein A., Bill P., Fancourt M., Polymyositis as a cause of malabsorption, S. Afr. Med., J 1997, 51, 176–178 Google Scholar

  • [16] Mansell P. I., Tattersall R. B., Balsitis M., Lowe J., Spiller R.C., Megaduodenum due to hollow visceral myopathy successfully managed by duodenoplasty and feeding jejunostomy, Gut., 1991, 32, 334–337 http://dx.doi.org/10.1136/gut.32.3.334CrossrefGoogle Scholar

  • [17] Hughes A. J., Ferguson I., Rankin E., Kane K., Polymyositis as a cause of total gut failure, Ann. Rheum. Dis., 2002, 61, 305–306 http://dx.doi.org/10.1136/ard.61.4.305CrossrefGoogle Scholar

  • [18] Tzioufas A. G., 2001, Antisynthetase syndrome. https://www.orpha.net/data/patho/GB/uk-antisynthetase.pdf (accessed 2013 Feb 08) Google Scholar

  • [19] Colglazier C. L., Sutej P. G., Laboratory testing in the rheumatic diseases: a practical review, South. Med. J., 2005, 98, 185–191 http://dx.doi.org/10.1097/01.SMJ.0000153572.22346.E9CrossrefGoogle Scholar

  • [20] Mammen A. L., Chung T., Christopher-Stine L., Rosen P., Rosen A., Doering K.R., et al., Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy, Arthritis Rheum., 2011, 63, 713–721 http://dx.doi.org/10.1002/art.30156Web of ScienceCrossrefGoogle Scholar

  • [21] Christopher-Stine L., Casciola-Rosen L. A., Hong G., Chung T., Corse A. M., Mammen A. L., A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy, Arthritis Rheum., 2010, 62, 2757–2766 http://dx.doi.org/10.1002/art.27572CrossrefWeb of ScienceGoogle Scholar

  • [22] Grable-Esposito P., Katzberg H. D., Greenberg S. A., Srinivasan J., Katz J., Amato A. A., Immunemediated necrotizing myopathy associated with statins, Muscle Nerve, 2010, 41, 185–190 Web of ScienceGoogle Scholar

  • [23] Marie I., Morbidity and mortality in adult polymyositis and dermatomyositis, Curr Rheumatol Rep, 2012, 14, 275–285 http://dx.doi.org/10.1007/s11926-012-0249-3CrossrefGoogle Scholar

  • [24] Ng M.K., Celermajer D.S., Glucocorticoid treatment and cardiovascular disease, Heart, 2004, 90, 829–830 http://dx.doi.org/10.1136/hrt.2003.031492CrossrefGoogle Scholar

About the article

Published Online: 2014-07-31

Published in Print: 2014-10-01

Citation Information: Open Medicine, Volume 9, Issue 5, Pages 619–624, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-013-0313-z.

Export Citation

© 2014 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Reactions Weekly, 2014, Volume 1517, Number 1, Page 38

Comments (0)

Please log in or register to comment.
Log in